dr. fenske discusses disease progression on ibrutinib in mcl
Published 5 years ago • 114 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:53
dr. fenske discusses ongoing study in frontline mcl
-
1:08
dr. fenske discusses targets under evaluation in mcl
-
1:05
dr. fenske on the utility of next-generation btk inhibitors in mcl
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:17
dr. woyach discusses progression on ibrutinib with the acquisition of resistance mutations
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
4:40
mcl: long-term safety/efficacy data with ibrutinib
-
1:08
dr. tam on the toxicity of ibrutinib plus venetoclax in mcl
-
1:08
dr. tam on the toxicities of ibrutinib plus venetoclax in mcl
-
1:41
dr. fenske on the future of daratumumab in mcl
-
1:06
dr. shah on options for ibrutinib-intolerant patients with mcl
-
1:22
dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:31
dr. woyach discusses progression on ibrutinib with the acquisition of resistance mutations
-
1:06
dr. goy on efficacy with ibrutinib in mcl
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
1:25
dr. goy discusses single-agent ibrutinib in mcl
-
3:04
considering off-label use of ibrutinib in mcl